AL Amyloidosis: Testing for Hidden Disease After Transplant
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks for 'minimal residual disease' (tiny traces of amyloid after treatment) in people with AL amyloidosis who have had a stem cell transplant. It helps doctors understand if more treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been newly diagnosed with AL amyloidosis (amyloid made from light chain proteins).
- You are eligible for and willing to have a stem cell transplant (ASCT).
- You have achieved a complete hematologic response (no detectable abnormal light chains) after 2–4 cycles of Dara-CyBorD chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NXC-201 against a standard combination treatment (daratumumab with cyclophosphamide, bortezomib, and dexamethasone) for people with newly diagnosed AL amyloidosis. The goal is to see if the new drug works better at targeting the abnormal proteins that cause organ damage.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.